Scarica l'app Stockscreener
7.22
7.32%
-0.57
Dopo l'orario di chiusura:
7.42
0.20
+2.77%
Precedente Chiudi:
$7.79
Aprire:
$7.63
Volume 24 ore:
162.23K
Relative Volume:
0.04
Capitalizzazione di mercato:
$62.81M
Reddito:
-
Utile/perdita netta:
$-6.42M
Rapporto P/E:
-1.289
EPS:
-5.6013
Flusso di cassa netto:
$-7.45M
1 W Prestazione:
-14.76%
1M Prestazione:
-23.03%
6M Prestazione:
-33.15%
1 anno Prestazione:
-63.33%
Intervallo 1D:
$7.01
$7.728
Intervallo di 1 settimana:
$7.01
$8.59
Portata 52W:
$1.80
$22.57
Cervomed Inc Stock (CRVO) Company Profile
Nome
Cervomed Inc
Settore
Industria
Telefono
(617) 744-4400
Indirizzo
20 PARK PLAZA, BOSTON
Confronta CRVO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
7.22 | 73.71M | 0 | -6.42M | -7.45M | -5.6013 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | Downgrade | D. Boral Capital | Buy → Hold |
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-12-05 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-18 | Iniziato | Chardan Capital Markets | Buy |
| 2024-07-26 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-15 | Iniziato | Canaccord Genuity | Buy |
| 2020-11-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Cervomed Inc Borsa (CRVO) Ultime notizie
CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of “Moderate Buy” by Analysts - Defense World
CervoMed Releases New Business and Financial Information - TipRanks
Pre-market Movers: CMRX, CPIX, PBM, CRVO... - RTTNews
Chardan Capital Raises Earnings Estimates for CervoMed - Defense World
Roth Capital Brokers Reduce Earnings Estimates for CervoMed - Defense World
Brokers Set Expectations for CervoMed Q2 Earnings - Defense World
Insider Buying: William Elder Acquires Additional Shares of Cerv - GuruFocus
CervoMed (NASDAQ:CRVO) Earns “Buy” Rating from D. Boral Capital - Defense World
CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates - MSN
CervoMed’s CFO Makes Bold Move with New Stock Purchase! - TipRanks
CervoMed First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Chardan keeps CervoMed stock Buy rating, $15 target post-results - Investing.com Australia
CervoMed (CRVO) Maintains Buy Rating with Stable Price Target | - GuruFocus
Chardan Adjusts Price Target on CervoMed to $15 From $14, Maintains Buy Rating - marketscreener.com
CervoMed (CRVO) Maintains Buy Rating with Stable Price Target | CRVO Stock News - GuruFocus
CervoMed Announces $50M Sales Agreement with Leerink - TipRanks
Chardan Capital Issues Positive Forecast for CervoMed (NASDAQ:CRVO) Stock Price - Defense World
CervoMed Inc. Reports Q1 2025 Financial Results - TipRanks
Chardan keeps CervoMed stock Buy rating, $15 target post-results By Investing.com - Investing.com South Africa
CervoMed Inc (CRVO) Q1 2025 Earnings: Revenue Beats Estimates at $1.9M, Net Loss Reported - GuruFocus
CervoMed (CRVO): Chardan Capital Raises Price Target | CRVO Stoc - GuruFocus
CervoMed (CRVO): Chardan Capital Raises Price Target | CRVO Stock News - GuruFocus
Cervomed Co Enters Sales Agreement With Leerink Partners LLC - marketscreener.com
CervoMed (CRVO) Financial Position and Funding Outlook | CRVO St - GuruFocus
CervoMed (CRVO) Exceeds Q1 Revenue Expectations Amid Promising T - GuruFocus
CervoMed Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
SEC Form 10-Q filed by CervoMed Inc. - Quantisnow
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
CervoMed Inc. Reports Positive Phase 2b Results for Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies and Plans Phase 3 Trial - Nasdaq
CervoMed (CRVO) to Release Earnings on Tuesday - Defense World
CervoMed Announces Executive Appointments and Changes - MSN
Mariner LLC Invests $30,000 in CervoMed Inc. (NASDAQ:CRVO) - Defense World
JPMorgan Chase & Co. Grows Position in CervoMed Inc. (NASDAQ:CRVO) - Defense World
CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference - GlobeNewswire
CRVO Shares Experience Surge in Value - knoxdaily.com
Head to Head Comparison: CervoMed (NASDAQ:CRVO) versus Schrödinger (NASDAQ:SDGR) - Defense World
Analysts Set CervoMed Inc. (NASDAQ:CRVO) Price Target at $27.50 - Defense World
What Will CervoMed Inc (NASDAQ: CRVO) Be Like In 2025 - Stocksregister
CervoMed Inc. Announces Executive Appointments and Officer Departure By Investing.com - Investing.com South Africa
CervoMed Inc. Announces Executive Appointments and Officer Departure - Investing.com Australia
CervoMed (CRVO) to Present Key Findings on Dementia Drug at Inte - GuruFocus
CervoMed (CRVO) Reports Positive Phase 2b Results for Neflamapim - GuruFocus
Cervomed Inc Azioni (CRVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):